Evaluating the Impact of a Risk Evaluation and Mitigation Strategy with Tolvaptan to Monitor Liver Safety in Patients with Autosomal Dominant Polycystic Kidney Disease.

Alvin Estilo, LaRee Tracy, Carol Matthews, Michele Riggen,Annette Stemhagen, Timothy Wilt, Anatoliy Krakovich, Charlotte Jones-Burton,Vinu George,Robert McQuade,Mirza Rahman

Clinical Kidney Journal（2022）

引用 6|浏览3

关键词

autosomal dominant polycystic kidney disease (ADPKD),drug-induced liver injury (DILI),liver safety,post-marketing surveillance,Risk Evaluation and Mitigation Strategy (REMS),tolvaptan

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要